{
    "clinical_study": {
        "@rank": "46848", 
        "arm_group": [
            {
                "arm_group_label": "cohort a CPA", 
                "arm_group_type": "Experimental", 
                "description": "Cohort A CPA high dose BID BI 207127/QD Faldaprevir and ribavirin"
            }, 
            {
                "arm_group_label": "cohort a CPB low dose", 
                "arm_group_type": "Experimental", 
                "description": "Cohort A CPB low dose BID BI 207127/QD Faldaprevir and ribavirin"
            }, 
            {
                "arm_group_label": "cohort a CPB high dose", 
                "arm_group_type": "Experimental", 
                "description": "Cohort A CPB high dose BID BI 207127/QD Faldaprevir and ribavirin"
            }, 
            {
                "arm_group_label": "cohort b control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Cohort B CPB placebo control"
            }, 
            {
                "arm_group_label": "cohort b active", 
                "arm_group_type": "Experimental", 
                "description": "Cohort B CPB BID BI 207127/QD Faldaprevir and ribavirin"
            }
        ], 
        "brief_summary": {
            "textblock": "Cohort A: Objective of Part 1a:  to assess the pharmacokenetic characteristics of  600 mg\n      BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected\n      patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120 mg QD\n      faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic\n      impairment (CPB) (Arm 2).\n\n      Cohort A: Objective of Part 1b (Arm 3): Part 1b will only be conducted if the\n      pharmacokenetics in Part 1a show that the 400 mg BID BI 207127 / 120 mg QD faldaprevir /\n      ribavirin regimen is inadequate to achieve therapeutic BI207127 and/or faldaprevir levels.\n      Part 1B will assess the pharmacokenetic characteristics of 600 mg BID BI 207127  / 120 mg QD\n      faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic\n      impairment (CPB). If arm 2 in part 1a has similar or higher PK than Arm 1, Part 1b (Arm 3)\n      will be skipped.\n\n      Cohort B: Main Objective Part 2:  To evaluate the safety, efficacy and PK of treatment with\n      120 mg of once daily (QD) faldaprevir for 24 weeks in combination with either 400 mg of\n      twice-daily (BID) BI 207127 or 600 mg of BID BI 207127 (depending on the outcome of Part 1)\n      and ribavirin (R) in a larger group of GT1b HCV infected patients with moderate hepatic\n      impairment (CPB)."
        }, 
        "brief_title": "BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Treatment na\u00efve and treatment experienced patients (prior relapse, interferon\n             intolerant, and [allowed in Cohort A only] prior partial response).\n\n          2. Chronic HCV infection of genotype 1 (GT1), sub-GT1b virus only.\n\n          3. Liver cirrhosis defined as Metavir Grade=4 or Ishak Grade =5 on liver biopsy or liver\n             stiffness of  =13 kPa on fibroscan.\n\n        Exclusion criteria:\n\n          1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) or mixed sub-GT1a/1b or undefined\n             diagnosed by genotypic testing at screening\n\n          2. Liver disease due to causes other than chronic HCV infection which may include but is\n             not limited to hemochromatosis, Wilson's disease, or autoimmune liver diseases.\n\n          3. HIV infection\n\n          4. Patients who have been previously treated with an investigational or approved DAA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830127", 
            "org_study_id": "1241.30", 
            "secondary_id": "2012-003534-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "cohort a CPB high dose", 
                "description": "24 weeks", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort b active", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127 high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort b control", 
                "description": "24 weeks", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPB high dose", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127 high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "Ribavirin placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort b control", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort b active", 
                "description": "24 weeks", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127 high dose placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPB low dose", 
                "description": "24 weeks", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "Faldaprevir placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPB low dose", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127 low dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127 low dose placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cohort a CPA", 
                "description": "24 weeks", 
                "intervention_name": "BI 207127 low dose", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Mesa", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1241.30.10003 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1241.30.10007 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Deland", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1241.30.10001 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1241.30.10012 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1241.30.10011 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "1241.30.10002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49004 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49005 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49008 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt am Main", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49006 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49001 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49003 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "1241.30.49007 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "1241.30.34005 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "1241.30.34002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "1241.30.34003 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "1241.30.34001 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1241.30.44002 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase III Randomised, Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Spain: Spanish Agency of Medicines", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "SVR12:  Plasma HCV RNA level less than 25 IU/mL at 12 weeks after End of Treatment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after End of Treatment"
        }, 
        "removed_countries": {
            "country": [
                "Canada", 
                "Ireland", 
                "Switzerland", 
                "France", 
                "Italy"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830127"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "SVR4:  Plasma HCV RNA level less than 25 IU/mL at 4 weeks after End of Treatment", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after End of Treatment"
            }, 
            {
                "measure": "SVR24:  Plasma HCV RNA level less than 25 IU/mL at 24 weeks after End of Treatment", 
                "safety_issue": "No", 
                "time_frame": "24 week after End of Treatment"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}